Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinase inhibitors in moderate to severe hidradenitis suppurativa
NCT04092452Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) (4 cohorts), sponsored by Pfizer. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 16 weeks. Started Dec 2019; status: completed.
02
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04092452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092452.